MedTrace Logo

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

NCT02617849 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-02-18

No results posted yet for this study

Summary

This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Conditions

  • Metastatic Malignant Melanoma

Interventions

DRUG

Pembrolizumab

200 mg IV every 3 weeks

DRUG

Carboplatin

AUC=6, every 3 weeks x 4

DRUG

Paclitaxel

175 mg/m2, every 3 weeks x 4

Sponsors & Collaborators

  • Wilson Miller

    lead OTHER

Principal Investigators

  • Wilson Miller, MD, PhD · Jewish General Hospital

  • Rahima Jamal, MD, PhD · CHUM, Hopital Notre-Dame

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-19
Primary Completion
2021-12-31
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02617849 on ClinicalTrials.gov